Search
IntraBio, which moved from Oxford, UK to Austin, Texas last year, received FDA approval in September for its modified amino acid, AQNEURSA, to treat neurological manifestations of Niemann-Pick type C
President and CEO Professor Mallory Factor KCNG describes the mechanism of the therapy and the company's commercial launch and hiring....
Jan 22
Biotech CEO Sisterhood: Mary Lynne Hedley shares advice on board makeup, running meetings, and other factors into having an effective board of directors
Interviewed by Sisterhood editorial board member Julia Owens, Dr. Hedley, who was the co-founder of TESARO and today is a member of...
Jan 21
Off Target Effects Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's potential impact on it
For the first episode of the new video podcast, Matt turns the tables on Brad Loncar and interviews him about his experiences and...
Jan 16
SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more
He highlights the company's current clinical programs, and talks about how thy are leveraging for the future the unique expertise in...
Jan 16
SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now
She describes how Siren is being built with a universal AAV platform, and is nearing its first IND in oncology. Plus, the fundraising...
Jan 16
SF Healthcare Week: The Co-Founder and CEO of Kardigan talks about this week's $300M series A financing to do precision medicine for cardiovascular disease
Tassos Gianakakos describes the round and the investors who participated in it, and hints at the personalized, biomarker driven approach...
Jan 16
SF Healthcare Week: Recursion Co-Founder & CEO Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets in development
He discusses the merger that completed towards the end of last year, Recursion's computational and wet lab abilities, cerebral cavernous...
Jan 15
SF Healthcare Week: The CEO of Ionis talks about over 30 years of developing RNA therapies, and a new chapter as a commercial forward company
Brett Monia discusses the approval of TRYNGOLZA and an important data readout this year in severe hypertriglyceridemia. Plus, the...
Jan 15
SF Healthcare Week: Biohaven CEO Vlad Coric talks degraders, ion channel programs, and ADCs
He describes updates given for the degrader programs targeting IgG, IgA nephropathy, and peripartum cardiomyopathy.. Plus, ion channel...
Jan 15
SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, multiple myeloma, and lupus
She describes how the company's HLA matching and CD19 relapse testing is playing out, when we can expect to see new data, and how the...
Jan 15
SF Healthcare Week: The CEO of Arvinas talks protein degradation, including about the industry's first phase 3 readout that is upcoming this quarter
John Houston describes what he believes are the keys to protein degradation, and discusses the company's monotherapy and combination...
Jan 15
SF Healthcare Week: After striking a transformational deal with Sanofi, Novavax is ramping up its vaccine pipeline
CEO John Jacobs describes the Sanofi deal, and combining Covid vaccines with flu vaccines. Plus, how the company is thinking about...
Jan 14
SF Healthcare Week: The CEO of Akeso talks about its PD1xVEGF, other bi-specific targets, and her opinion of China's position in the global biotech ecosystem
Chairman & CEO Michelle Xia describes the clinical trial that was run comparing the company's PD1xVEGF vs Akeso, development plans...
Jan 14
SF Healthcare Week: With two commercial products providing cash flow, and more in development, the new CEO of Acadia Pharma is ready to do deals
Catherine Owen Adams walks us through the latest on NUPLAZID and DAYBUE, and products in development for Alzheimer's psychosis,...
Jan 14
SF Healthcare Week: Roivant CEO Matt Gline provides an update on the 'vant ecosystem
He discusses key data in the year ahead including from Immunovant and Priovant. Plus, an update on the lawsuits regarding covid vaccine...
Jan 13
SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings
He talks about todays M&A heavy news and the market reaction to it, and comments on Xenon, Madrigal, Nurix, and Wave.
Jan 13
SF Healthcare Week: Teva CEO Richard Francis discusses the TL1A space, and the how company's overall focus has transformed to innovation
He describes how he believes the TL1A compares to others in the field, other programs in the company's innovation pipeline, and the...
Jan 13
SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development
He shares his thoughts on Moderna's transition, what policies he would like to see promoted in government, competing with China, and the...
Jan 13
SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks
He discusses news from Biogen and Regeneron, and shares his top picks Xenon, Soleno, and Lexeo.
Jan 13
BioVenture VoiCes Episode 10: Curie.Bio's Alexis Borisy
The Co-Founder and Operating Chairman of Curie.Bio, and serial entrepreneur, shares experiences from his early life, CombinatoRx,...
Jan 13
.png){kind=logo}
